Jupiter Neurosciences Files 8-K: Material Agreement Announced

TL;DR

JUPITER NEUROSCIENCES (JBNA) filed an 8-K for a material definitive agreement on 12/15/24. Details TBD.

AI Summary

Jupiter Neurosciences, Inc. announced on December 15, 2024, that it entered into a Material Definitive Agreement. The company also filed financial statements and exhibits as part of this report. The filing does not specify the nature of the agreement or any associated financial figures.

Why It Matters

This 8-K filing indicates a significant development for Jupiter Neurosciences, Inc., potentially involving a new partnership, acquisition, or financing, which could impact its future operations and stock value.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the agreement and its financial implications introduces uncertainty.

Key Players & Entities

• JUPITER NEUROSCIENCES, INC. (company) — Registrant
• December 15, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-41265 (identifier) — Commission File Number
• 47-4828381 (identifier) — IRS Employer Identification No.
• 1001 North US HWY 1 , Suite 504 Jupiter , FL 33477 (address) — Address of Principal Executive Offices
• (561) 406-6154 (phone_number) — Registrant's Telephone Number

FAQ

From the Filing

0001493152-24-050801.txt : 20241219 0001493152-24-050801.hdr.sgml : 20241219 20241219170018 ACCESSION NUMBER: 0001493152-24-050801 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 22 CONFORMED PERIOD OF REPORT: 20241215 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241219 DATE AS OF CHANGE: 20241219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 241564069 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 8-K 1 form8-k.htm false 0001679628 0001679628 2024-12-15 2024-12-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): December 15, 2024   JUPITER NEUROSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter)   Delaware   001-41265   47-4828381 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   1001 North US HWY 1 , Suite 504 Jupiter , FL   33477 (Address of Principal Executive Offices)   (Zip Code)   (561) 406-6154 (Registrant’s Telephone Number, Including Area Code)   N/A (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   JUNS   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 1.01 Entry into a Material Definitive Agreement.   On December 15, 2024, Jupiter Neurosciences, Inc. (the “Company”) entered into a Strategic Services Agreement (the “Dominant Treasure Agreement”) with Dominant Treasure Health Company Limited (“Dominant Treasure”). Pursuant to the terms of the Dominant Treasure Agreement, Dominant Treasure agreed to provide certain services to the Company to assist the Company in accelerating the Company’s desire to get its products developed and distributed in the Southeast Asian market. I